Navamedic ASA Reports Promising Growth Amid Challenges in 2025 Financials Navamedic ASA showcases solid revenue growth and strategic successes in its latest financial report for the first half of 2025, emphasizing resilience in its antibiotic portfolio.

Navamedic ASA Reports Promising Growth Amid Challenges in 2025 Financials #Norway #Oslo #Navamedic_ASA #Antibiotics_Portfolio #Flexilev_Product